-
Product Insights
NewThymidylate Synthase – Drugs In Development, 2024
The Thymidylate Synthase pipeline drugs market research report outlays comprehensive information on the Thymidylate Synthase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Infectious Disease, and Dermatology which include indications of Pancreatic Cancer, Gastric Cancer, Cryptococcal Meningitis, Bacterial Infections, Actinic (Solar) Keratosis, and Hypertrophic Scars. It also reviews key players involved in Thymidylate Synthase targeted therapeutics...
-
Product Insights
NewGPI Anchored Wall Transfer Protein 1 – Drugs In Development, 2024
The GPI Anchored Wall Transfer Protein 1 pipeline drugs market research report outlays comprehensive information on the GPI Anchored Wall Transfer Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Infectious Disease which include indications of Cryptococcal Meningitis, and Candidiasis. It also reviews key players involved in GPI Anchored Wall Transfer Protein 1 targeted therapeutics development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vebreltinib ER in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vebreltinib ER in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib ER in Colon Cancer Drug Details: Vebreltinib ER (Vambiru)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vebreltinib ER in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vebreltinib ER in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib ER in Pancreatic Cancer Drug Details: Vebreltinib ER (Vambiru)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vebreltinib ER in Central Nervous System (CNS) Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vebreltinib ER in Central Nervous System (CNS) Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib ER in Central Nervous System (CNS)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vebreltinib ER in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vebreltinib ER in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib ER in Esophageal Cancer Drug Details: Vebreltinib ER (Vambiru)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vebreltinib ER in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vebreltinib ER in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib ER in Leptomeningeal Disease (Neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LR-20062 in Pertussis (Whooping Cough)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LR-20062 in Pertussis (Whooping Cough) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LR-20062 in Pertussis (Whooping Cough) Drug Details: LR-20062 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Paxalisib in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paxalisib in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paxalisib in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amphotericin B in Cryptococcal Meningitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amphotericin B in Cryptococcal Meningitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amphotericin B in Cryptococcal Meningitis Drug Details: Amphotericin B (MAT-2203)...